the aid library

LIST OPTIONS

Filter

2190

Gender-based violence and child protection among Syrian refugees in Jordan, with a focus on early marriage

UNWomen (2013)

Findings from this report reveal that, rates of early marriage are high, a significant percentage of children contribute to the household’s income or are its main source of income, and restrictions on the mobility of women and girls constrain their participation in social and economic activities a... more

Download (5647)

View PDF (1993)

Technical Guidelines for Integrated Disease Surveillance and Response in Sierra Leone

GOVERNMENT OF SIERRA LEONE MINISTRY OF HEALTH AND SANITATION (2008) C1

Download (328)

View PDF (305)

App for its Medical Eligibility Criteria for Contraceptive Use

Johns Hopkins Bloomberg School of Public HealthCenter for Communication Programs and World Health Organization (2022) C_WHO

Recommendations on the initiation and continuing use of nine common types of contraceptive methods are covered by the tool. In addition to looking at individual medical conditions or characteristics, users may also easily combine multiple conditions or characteristics and view the guidance on each c... more

Download (572)

View PDF (694)

Zoonotic diseases of public health importance

National Institue of communicable Diseases, India (1998) C1

Download (984)

View PDF (1309)

Intermittent preventive treatment (IPT) of malaria in pregnancy. Training manual for health providers

Ministry of Health Ghana; Ghana Health Service GHSNMCP (2005) C1

Facilitator's Guide

Download (290)

View PDF (404)

Five-Year Strategic Plan for Young People's Health (2016-2020)

The Republic of the Union of Myanmar, Ministry of Health and Sports (2017) C1

The National Strategic Plan is based on the following guiding principles:
1) Life-course approach: adolescence is a key decade in the course of life that inﬂuences the health outcomes later in life.
2) Comprehensive approach: It recognizes the cross cutting health and development needs o... more

Download (228)

View PDF (251)

Definição e categorização do momento da transmissão vertical do SARS-CoV-2 Informe científico 8 de fevereiro de 2021

Organização Mundial da Saúde (OMS) OPAS, OMS (2021) C_WHO

Definition and categorization of the time of vertical transmission of SARS-CoV-2 Scientific report 8 February 2021

Download (233)

View PDF (240)

Principles in using psychotropic medication in children and adolescents

B. Vitiello IACAPAP (2012) C2

Introduction Chapter A.7

Download (422)

View PDF (667)

Facility based integrated management of neonatal and childhood illness (F-IMNCI) - Facilitators Guide (Facility Based Care)

Ministry of Health and Family Welfare Government of India; WHO; UNICEF (2009) C_WHO

Download (299)

View PDF (277)

Inter-Agency Reproductive Health Kits 6th Edition - Manual

Inter-Agency Working Group on Reproductive Health in Crisis IAWG and UNFPA (2021) C1

Download (262)

View PDF (287)

Mental Health in the times of COVID-19 Pandemic

National Institute of Mental Health & Neurosciences, Bengaluru India; Dept. of Psychiatry (2020) CC

Guidance for General Medical and Specialised Mental Health Care Settings

Download (274)

View PDF (261)

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

World Health Organization WHO (2022) C_WHO

Download (687)

View PDF (1029)

Independent Monitoring Board of the Global Polio Eradication Initiative (Fifteenth Report: December 2017)

Global Polio Eradication Initiative (2017) C1

The report reviews progress with the task of planning and implementing measures necessary to secure a completely polio-free world. It also examines actions aimed at ensuring successful transfer of polio assets, innovations developed and lessons learned to countries’ public health programmes and ot... more

Download (393)

View PDF (152)

National Guidelines for Integrated Diseases Surveillance and Response Uganda

World Health Organization WHO, Regional Office of Africa; Ministry of Health Uganda (2021) C_WHO

3rd edition. In 2001, Uganda adapted the Integrated Disease Surveillance and Response (IDSR) developed by World Health Organization (WHO) for member states in African region. The Ministry of Health has been implementing the IDSR strategy since then with success across the country. This strategy prov... more

Download (160)

View PDF (219)

Recomendaciones para el tratamiento hospitalario de la COVID-19 en pacientes adultos ( Version 10, 2020)

G, Zambrano, E Salgato, F. M. Moyano et al. (2020) CC

Recommendations for in-patient management of COVID-19 in adult patients Version 10, November 2020.

External Link

Guide to introducing human rabies vaccine into national immunization programmes: Handbook

World Health Organization WHO (2022) C_WHO

Rabies is fatal, vaccine-preventable disease responsible for an estimated 59,000 human deaths each year. Most cases are transmitted by dogs, and most deaths occur in underserved populations in Africa and Asia. Approximately 40% of deaths occur in children.

Download (157)

View PDF (209)

Pediatric oncology nursing practice in Latin America and the Caribbean

Pan American Health Organisation PAHO (2024) C_WHO

One of the main aims of the WHO Global Initiative for Childhood Cancer and the CureAll Americas framework is to strengthen centers of excellence and promote the training of the health workforce, especially pediatric oncology nurses, specialized in nursing care for children and adolescents with cance... more

Download (502)

View PDF (1115)

The Wise List 2015

Stockholm Drug and Therapeutics Committee (2015) C_WHO

with recommended essential medicines for common diseases in patients in Stockholm County Council (Healthcare Region), Sweden

Download (1375)

View PDF (1557)

Basic Epidemiology

Bonita, R.; R.Beaglehole, and T. Kjellström World Health Organization WHO (2006) C_WHO

2nd edition

Download (345)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more